Nitric oxide inhalation in the treatment of right ventricular dysfunction following left ventricular assist device implantation

Frank Wagner, Michael Dandel, Grischa Günther, Matthias Loebe, Ingram Schulze-Neick, Ullrich Laucke, Rainer Kuhly, Yuguo Weng, Roland Hetzer

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Background: Following left ventricular assist device (LVAD) implantation in end-stage heart failure, the management of right ventricular dysfunction presents a therapeutic problem unresolved by conventional drug therapy (catecholamines, nitrates, and prostacyclin). This study was performed to investigate the effects of supplemental inhalation of nitric oxide (NO), a selective pulmonary vasodilator, postoperatively and prospectively. Methods and Results: Intraindividual dose titration of NO was performed (0 to 40 ppm) according to a standardized protocol. Thereafter treatment was continued with the individually most effective dose of NO (25 to 40 ppm). In 8 consecutive male patients presenting with right ventricular dysfunction postoperatively, a significant dose-dependent improvement in hemodynamic function was observed: pulmonary vascular resistance decreased from 336±110 to 210±59 dynes · s · cm-5 (P<.0001), cardiac index rose from 2.0±0.4 to 2.7±0.4 L · min-1 m-2 (P<.003) at 40 ppm; doses of >20 ppm were effective in increasing cardiac index (P<.05). With continuous NO inhalation up to 48 hours, pulmonary vascular resistance decreased further to 155±33 dynes · s · cm-5 (P<.0001) as the cardiac index increased to 3.3±0.6 L · min-1 · m-2 (P<.003). Pulmonary artery pressure decreased (P<.0001) as did systemic vascular resistance with hemodynamic improvement (P<.01). Central venous pressure and mean arterial pressure remained unchanged. Right ventricular, ejection fraction at transesophageal echocardiography increased from 24±7% to 44±7% (P<.01) at the end of the study, and right ventricular end-diastolic volume decreased (P<.05). Weaning from NO therapy was successful at 2 to 8 days, and all patients were extubated. Right ventricular function remained stable thereafter. Conclusions: In the treatment of right ventricular dysfunction following LVAD implantation, inhalation of NO markedly decreased fight ventricular afterload by its selective vasodilating effects on the pulmonary circulation without producing systemic hypotension; this merits further evaluation.

Original languageEnglish (US)
JournalCirculation
Volume96
Issue number9 SUPPL.
StatePublished - Nov 4 1997
Externally publishedYes

Fingerprint

Right Ventricular Dysfunction
Heart-Assist Devices
Inhalation
Nitric Oxide
Vascular Resistance
Stroke Volume
Therapeutics
Hemodynamics
Right Ventricular Function
Central Venous Pressure
Pulmonary Circulation
Transesophageal Echocardiography
Epoprostenol
Weaning
Vasodilator Agents
Nitrates
Hypotension
Pulmonary Artery
Catecholamines
Arterial Pressure

Keywords

  • Heart failure
  • Heart-assist device
  • Hemodynamics
  • Nitric oxide

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Wagner, F., Dandel, M., Günther, G., Loebe, M., Schulze-Neick, I., Laucke, U., ... Hetzer, R. (1997). Nitric oxide inhalation in the treatment of right ventricular dysfunction following left ventricular assist device implantation. Circulation, 96(9 SUPPL.).

Nitric oxide inhalation in the treatment of right ventricular dysfunction following left ventricular assist device implantation. / Wagner, Frank; Dandel, Michael; Günther, Grischa; Loebe, Matthias; Schulze-Neick, Ingram; Laucke, Ullrich; Kuhly, Rainer; Weng, Yuguo; Hetzer, Roland.

In: Circulation, Vol. 96, No. 9 SUPPL., 04.11.1997.

Research output: Contribution to journalArticle

Wagner, F, Dandel, M, Günther, G, Loebe, M, Schulze-Neick, I, Laucke, U, Kuhly, R, Weng, Y & Hetzer, R 1997, 'Nitric oxide inhalation in the treatment of right ventricular dysfunction following left ventricular assist device implantation', Circulation, vol. 96, no. 9 SUPPL..
Wagner, Frank ; Dandel, Michael ; Günther, Grischa ; Loebe, Matthias ; Schulze-Neick, Ingram ; Laucke, Ullrich ; Kuhly, Rainer ; Weng, Yuguo ; Hetzer, Roland. / Nitric oxide inhalation in the treatment of right ventricular dysfunction following left ventricular assist device implantation. In: Circulation. 1997 ; Vol. 96, No. 9 SUPPL.
@article{ed3baa05cf2d4087be8323e49cb8cb90,
title = "Nitric oxide inhalation in the treatment of right ventricular dysfunction following left ventricular assist device implantation",
abstract = "Background: Following left ventricular assist device (LVAD) implantation in end-stage heart failure, the management of right ventricular dysfunction presents a therapeutic problem unresolved by conventional drug therapy (catecholamines, nitrates, and prostacyclin). This study was performed to investigate the effects of supplemental inhalation of nitric oxide (NO), a selective pulmonary vasodilator, postoperatively and prospectively. Methods and Results: Intraindividual dose titration of NO was performed (0 to 40 ppm) according to a standardized protocol. Thereafter treatment was continued with the individually most effective dose of NO (25 to 40 ppm). In 8 consecutive male patients presenting with right ventricular dysfunction postoperatively, a significant dose-dependent improvement in hemodynamic function was observed: pulmonary vascular resistance decreased from 336±110 to 210±59 dynes · s · cm-5 (P<.0001), cardiac index rose from 2.0±0.4 to 2.7±0.4 L · min-1 m-2 (P<.003) at 40 ppm; doses of >20 ppm were effective in increasing cardiac index (P<.05). With continuous NO inhalation up to 48 hours, pulmonary vascular resistance decreased further to 155±33 dynes · s · cm-5 (P<.0001) as the cardiac index increased to 3.3±0.6 L · min-1 · m-2 (P<.003). Pulmonary artery pressure decreased (P<.0001) as did systemic vascular resistance with hemodynamic improvement (P<.01). Central venous pressure and mean arterial pressure remained unchanged. Right ventricular, ejection fraction at transesophageal echocardiography increased from 24±7{\%} to 44±7{\%} (P<.01) at the end of the study, and right ventricular end-diastolic volume decreased (P<.05). Weaning from NO therapy was successful at 2 to 8 days, and all patients were extubated. Right ventricular function remained stable thereafter. Conclusions: In the treatment of right ventricular dysfunction following LVAD implantation, inhalation of NO markedly decreased fight ventricular afterload by its selective vasodilating effects on the pulmonary circulation without producing systemic hypotension; this merits further evaluation.",
keywords = "Heart failure, Heart-assist device, Hemodynamics, Nitric oxide",
author = "Frank Wagner and Michael Dandel and Grischa G{\"u}nther and Matthias Loebe and Ingram Schulze-Neick and Ullrich Laucke and Rainer Kuhly and Yuguo Weng and Roland Hetzer",
year = "1997",
month = "11",
day = "4",
language = "English (US)",
volume = "96",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "9 SUPPL.",

}

TY - JOUR

T1 - Nitric oxide inhalation in the treatment of right ventricular dysfunction following left ventricular assist device implantation

AU - Wagner, Frank

AU - Dandel, Michael

AU - Günther, Grischa

AU - Loebe, Matthias

AU - Schulze-Neick, Ingram

AU - Laucke, Ullrich

AU - Kuhly, Rainer

AU - Weng, Yuguo

AU - Hetzer, Roland

PY - 1997/11/4

Y1 - 1997/11/4

N2 - Background: Following left ventricular assist device (LVAD) implantation in end-stage heart failure, the management of right ventricular dysfunction presents a therapeutic problem unresolved by conventional drug therapy (catecholamines, nitrates, and prostacyclin). This study was performed to investigate the effects of supplemental inhalation of nitric oxide (NO), a selective pulmonary vasodilator, postoperatively and prospectively. Methods and Results: Intraindividual dose titration of NO was performed (0 to 40 ppm) according to a standardized protocol. Thereafter treatment was continued with the individually most effective dose of NO (25 to 40 ppm). In 8 consecutive male patients presenting with right ventricular dysfunction postoperatively, a significant dose-dependent improvement in hemodynamic function was observed: pulmonary vascular resistance decreased from 336±110 to 210±59 dynes · s · cm-5 (P<.0001), cardiac index rose from 2.0±0.4 to 2.7±0.4 L · min-1 m-2 (P<.003) at 40 ppm; doses of >20 ppm were effective in increasing cardiac index (P<.05). With continuous NO inhalation up to 48 hours, pulmonary vascular resistance decreased further to 155±33 dynes · s · cm-5 (P<.0001) as the cardiac index increased to 3.3±0.6 L · min-1 · m-2 (P<.003). Pulmonary artery pressure decreased (P<.0001) as did systemic vascular resistance with hemodynamic improvement (P<.01). Central venous pressure and mean arterial pressure remained unchanged. Right ventricular, ejection fraction at transesophageal echocardiography increased from 24±7% to 44±7% (P<.01) at the end of the study, and right ventricular end-diastolic volume decreased (P<.05). Weaning from NO therapy was successful at 2 to 8 days, and all patients were extubated. Right ventricular function remained stable thereafter. Conclusions: In the treatment of right ventricular dysfunction following LVAD implantation, inhalation of NO markedly decreased fight ventricular afterload by its selective vasodilating effects on the pulmonary circulation without producing systemic hypotension; this merits further evaluation.

AB - Background: Following left ventricular assist device (LVAD) implantation in end-stage heart failure, the management of right ventricular dysfunction presents a therapeutic problem unresolved by conventional drug therapy (catecholamines, nitrates, and prostacyclin). This study was performed to investigate the effects of supplemental inhalation of nitric oxide (NO), a selective pulmonary vasodilator, postoperatively and prospectively. Methods and Results: Intraindividual dose titration of NO was performed (0 to 40 ppm) according to a standardized protocol. Thereafter treatment was continued with the individually most effective dose of NO (25 to 40 ppm). In 8 consecutive male patients presenting with right ventricular dysfunction postoperatively, a significant dose-dependent improvement in hemodynamic function was observed: pulmonary vascular resistance decreased from 336±110 to 210±59 dynes · s · cm-5 (P<.0001), cardiac index rose from 2.0±0.4 to 2.7±0.4 L · min-1 m-2 (P<.003) at 40 ppm; doses of >20 ppm were effective in increasing cardiac index (P<.05). With continuous NO inhalation up to 48 hours, pulmonary vascular resistance decreased further to 155±33 dynes · s · cm-5 (P<.0001) as the cardiac index increased to 3.3±0.6 L · min-1 · m-2 (P<.003). Pulmonary artery pressure decreased (P<.0001) as did systemic vascular resistance with hemodynamic improvement (P<.01). Central venous pressure and mean arterial pressure remained unchanged. Right ventricular, ejection fraction at transesophageal echocardiography increased from 24±7% to 44±7% (P<.01) at the end of the study, and right ventricular end-diastolic volume decreased (P<.05). Weaning from NO therapy was successful at 2 to 8 days, and all patients were extubated. Right ventricular function remained stable thereafter. Conclusions: In the treatment of right ventricular dysfunction following LVAD implantation, inhalation of NO markedly decreased fight ventricular afterload by its selective vasodilating effects on the pulmonary circulation without producing systemic hypotension; this merits further evaluation.

KW - Heart failure

KW - Heart-assist device

KW - Hemodynamics

KW - Nitric oxide

UR - http://www.scopus.com/inward/record.url?scp=0343683328&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0343683328&partnerID=8YFLogxK

M3 - Article

C2 - 9386113

AN - SCOPUS:0343683328

VL - 96

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 9 SUPPL.

ER -